Volta Medical has announced €36 million in new series B funding, bringing the total capital raised to over €70 million.
The company is developing artificial intelligence (AI) solutions to assist electrophysiologists in treating complex cardiac arrhythmias such as atrial fibrillation (AF).
The funding round was led by US-based Vensana Capital with co-investment from Lightstone Ventures and existing investor Gilde Healthcare. The funding will help accelerate new product development, support additional clinical trials, prepare for full-scale US commercialisation, and pursue further regulatory approvals, Volta Medical said in a press release.
The company’s lead product, VOLTA VX1, is designed to help guide physicians with identification and real-time annotation of dispersed electrograms on 3D anatomical and electrical maps of the heart.
“There is a critical need to improve precision and consistency in cardiac ablation procedures for patients with persistent AF,” said Theophile Mohr Durdez, Volta Medical CEO and co-founder. “With half of these patients requiring repeat treatments, clinicians need tools that enable them to better understand the disease and drastically improve patient outcomes. We believe VOLTA’s VX1 has the potential to do just that in a consistent, reproducible way. We are most grateful to the teams at Vensana, Lightstone, and Gilde for their support and confidence as we partner to further validate our products and expand access to it globally.”